Live Green Hemp

Live Green Hemp Live Green Hemp is an American CBD brand. Live Green CBD is 100% Natural, 99%+ Pure CBD manufactured in controlled, certified labs.

.🚨🐶Looking for a healthy dog treat? Our Live Green H**p CBD treats for dogs are a quick and easy method to give your bes...
06/10/2025

.🚨🐶Looking for a healthy dog treat? Our Live Green H**p CBD treats for dogs are a quick and easy method to give your best friend the right amount of pure, h**p-derived CBD in a tasty, crunchy hard chew that he'll love. 💕
Remembering Wade Laughter, the Unsung Hero of CBD

Wade Laughter passed away last week after a long battle with cancer. Beloved within the cannabis community as the modest, softspoken horticulturist with a big heart and a great last name, Wade is one of the unsung heroes of botanical CBD that took root in northern California in the early 2010s. At that time, hardly anyone knew about nonintoxicating cannabidiol and its remarkable therapeutic potential outside of a small group of scientists who were studying the endocannabinoid system. Word about CBD started to spread within medical ma*****na circles when a handful of CBD-rich cannabis cultivars were identified by newly established analytical labs servicing the nascent cannabis industry.

One of these CBD-rich varietals was “Harlequin,” so named by Wade Laughter, who didn’t take credit for breeding it. He said he merely discovered it. And we were very fortunate that he did. With CBD emerging as the exciting new kid on the cannabinoid block, several early adopters who had access to rare CBD-rich genetics were initially skittish about releasing their proprietary property. Not so with Wade Laughter.

Wade didn’t feel like he was the rightful owner of Harlequin. Nor was anyone else. He had been gifted this plant serendipitously, and he would gift it back to the community. He opted to make Harlequin available to anyone who was interested in growing it and exploring its healing attributes. Harlequin clones began to “seed” the California cannabis landscape, and soon Wade’s gift popped up in other states, as well. Thus began an unsupervised, mass-based medical experiment, a grassroots laboratory experiment in democracy, enabled by Laughter’s decision to share Harlequin with the world.

What would happen when a lot of people consumed CBD-rich cannabis? The preclinical science — attesting to the compound’s anti-inflammatory, anticonvulsant, anti-tumoral, neuroprotective, and analgesic properties — was nothing short of jaw-dropping. Thus far, however, most of the scientific studies involved single-molecule CBD tested on mice, rather than whole-plant CBD-rich cannabis flower and oil extract, which is what Wade was providing in California.

I grew some Harlequin in my backyard in 2011 and 2012. It was a squat, indica-looking plant, three-and-a-half-feet tall, very bushy with huge odiferous purple-pinkish colas oozing medicated goo that contained a significant amount of both CBD and THC. This gorgeous botanical tested at close to a 1:1 CBD:THC ratio. The CBD:THC ratio, which fluctuated from garden to garden, was influenced by how long these plants stayed in the ground. (A somewhat earlier harvest might register 3:2 CBD:THC, while a later harvest might shift it to 2:3 CBD:THC.)

Some of my humble harvest, I later learned, travelled to the east coast and found its way to the stash of Harvard professor emeritus and prominent medical cannabis advocate Dr. Lester Greenspan, who sang the praises of Harlequin as a pleasant energizer and uplifting balm for stiff seniors. Harlequin was euphoria-inducing, but in a somewhat different way from the ubiquitous THC-dominant fare. CBD seemed to lower the ceiling on the THC high while extending its duration.

In the early going THC, The High Causer, was always a key part of the CBD-rich equation. Within a few years, however, Harlequin and several other cannabis chemovars with roughly equal parts CBD and THC — Jamaican Lion, OmRita RX, Blue Jay Way (a True Blueberry/OG Kush cross), and Lawrence Ringo’s Sour Tsunami — were overshadowed by a surge of popular interest in nonintoxicating, high-CBD/low-THC cannabis oil extracts, misconstrued as “h**p” and much sought-after as an alternative treatment for epilepsy.

While a green rush of investors and grifters went all in on the cannabis that doesn’t get you high (until the market for over-produced CBD isolate crashed), Wade Laughter stayed the course as the curator of the “House of Harlequin,” which he established and maintained in Grass Valley with his partner Monica Senter. Wade was a key figure in the Caladrius Netwok, a nonprofit that provided cannabis-based medicine (flower and full-spectrum extract) to terminally ill and catastrophically ill children.

Wade dedicated his life to helping others, no strings attached, without expecting a return favor. His kindness came from a deep place, “a foundation of true selflessness,” as one of Wade’s close friends put it. “He gave freely, with an open heart, without making others feel small. He served quietly without needing applause. He stood beside the vulnerable, not above them.”

The post Remembering Wade Laughter, the Unsung Hero of CBD appeared first on Project CBD.

**p

Wade Laughter passed away last week after a long battle with cancer. Beloved within the cannabis community as the modest, softspoken horticulturist with a big

.🚨🐶Looking for a healthy dog treat? Our Live Green H**p CBD treats for dogs are a quick and easy method to give your bes...
04/17/2025

.🚨🐶Looking for a healthy dog treat? Our Live Green H**p CBD treats for dogs are a quick and easy method to give your best friend the right amount of pure, h**p-derived CBD in a tasty, crunchy hard chew that he'll love. 💕
CBD Topical Medicine: What Does the Science Say?

Consider it a testament to the ubiquity and flexibility of the endocannabinoid system: we can inhale medicinal cannabinoids via combustion or vaporization; ingest them via food or drink; and absorb them directly through the skin, the body’s largest organ.

This latter category is broader and more complex than many of us give it credit for. Inside the mouth, it includes both buccal (between the gums and cheek, as with a lozenge) and sublingual (under the tongue, as with a tincture) modes of absorption.

Everywhere else, it includes two additional routes that work in very different ways: topically, via cannabinoid receptors and secondary targets including TRP (“trip”) channels, PPARs (nuclear receptors), and serotonin receptors that are expressed widely in skin cells and superficial tissues; and transdermally, by entering the bloodstream through the skin.

Advantages and disadvantages

Traditional topicals – including water-based lotions and creams and oil-based balms and salves – offer a quick onset time, no psychoactivity, and the potential to treat not only aches, pains, and inflammation, but also skin conditions like psoriasis and eczema. On the other hand, they’re short-acting, relatively low in bioavailability, and limited to the area to which they’re applied.

Transdermal or “skin-crossing” formulations, meanwhile, are systemic. They act on the entire body (and thus may produce mild psychoactivity if THC is involved); they also last longer, and take effect more slowly. Such products rely on chemical enhancers (called “excipients”) like ethanol, propylene glycol, oleic acid, and even terpenes to help cannabinoids sneak past the skin barrier and into the bloodstream. They also employ special delivery systems like adhesive patches, hydrogels, and nano-emulsions.

Of course, what matters most to patients and clinicians is whether topical and transdermal cannabinoids really work. Much of the research to date has focused on testing cannabidiol or CBD’s ability to treat various forms of pain through a variety of molecular mechanisms – either locally, as with arthritis, muscle soreness, or inflammatory skin conditions; or systemically, for chronic ailments requiring a more controlled and sustained release.

So what do the studies say?

Clinical benefits?

A May 2024 article in the International Journal of Molecular Sciences assesses efforts thus far using CBD to treat inflammatory pain (such as in arthritis) via transdermal delivery systems. It reviews about half a dozen such studies, plus another ten looking at transdermal CBD for other conditions, including drug addiction, neurodegeneration, skin cancer, wound healing, and epilepsy.

Though the Canada-based authors conclude that transdermal delivery of CBD “shows great promise” and represents “a potential novel treatment for chronic inflammatory pain,” they also acknowledge that the jury is still out on its ability to achieve that key benchmark of offering “tangible clinical benefits.”

“A lot of work remains to be done,” they write.

About nine months earlier, another review by a team of Thai researchers appeared in the journal Cannabis and Cannabinoid Research . In this case, the focus was on both topical (local) and transdermal (systemic) formulations. The authors identified a total of just eight studies that met their criteria. Ultimately, they concluded that the available data on pain and other outcomes was unreliable, with a high risk of bias. “New clinical trials are urgently needed,” they repeat in a familiar refrain.

Literature review

In our own literature review, Project CBD identified four newer studies that were not included in the abovementioned reviews. Three address strictly topical/local formulations and one addresses a transdermal formulation. The findings are mixed.

A July 2024 article in Cannabis and Cannabinoid Research evaluates a topical CBD cream’s ability to relieve muscle soreness after exercise. Researchers with the University of Kentucky randomized 28 men and women (n=15 and 13, respectively) in their early and mid-20s to perform a series of lower-body resistance exercises, then do one of the following: a) apply a CBD-containing cream (~100mg) to their quadriceps; b) apply a placebo cream; or c) apply neither and just sit and rest.

Next the researchers administered questionnaires and a few exercise tests to ascertain muscle soreness and physical performance. Their findings after three days of repeating the protocol? Placebo recipients reported the most recovery and relief, while the CBD cream appeared to have no significant effects.

A 2022 paper in The Journal of Arthroplasty evaluating the ability of topical CBD to reduce acute localized pain after knee replacement surgery comes to a similar conclusion. In this double-blinded, placebo-controlled trial, 80 patients were randomly assigned to apply either topical CBD, essential oil, CBD and essential oil, or a placebo three times daily for two weeks following the operation.

On postoperative days 0, 1, 2, 7, 14, and 42, researchers with Thomas Jefferson University in Philadelphia collected data on patient pain, sleep, and opioid use. But upon analyzing the data, they found no significant relationship between CBD use and any of these outcomes.

A killer app for pain?

However, other studies from the last few years have come to opposite conclusions. For example, a phase-two double-blinded, randomized, controlled trial of topical CBD for the treatment of arthritis of the thumb, written up in the Journal of Hand Surgery in July 2022 underscores CBD’s analgesic potential.

University of Virginia researchers randomized 18 participants to receive a twice-daily treatment of either shea butter alone or shea butter with CBD. After a one-week washout period, participants switched groups. This time the results indicated that treatment with topical CBD led to significant improvements in a variety of self-reported measures including pain and disability.

Finally, a May 2024 article in Scientific Reports details the findings of an open-label feasibility trial – meaning it lacked a placebo control but may point the way toward a more rigorous clinical trial – where 15 patients with hand osteoarthritis applied a transdermal CBD gel three times a day for four weeks.

Self-reported pain ratings significantly declined over time. Self-reported fatigue, stiffness, and anxiety all improved. And grip strength as measured by a Bluetooth-connected squeeze ball increased. During a subsequent one-week washout phase, pain and grip strength reverted back towards baseline.

“Transdermal CBD gel may have a beneficial effect on pain and grip strength in participants with symptomatic hand osteoarthritis, but requires further exploration,” the authors conclude. “[Future] research should incorporate a double-blind, randomized study design with greater participant numbers and more comprehensive pharmacokinetic and biomarker analysis.”

Nate Seltenrich, Project CBD contributing writer, is the author of the column Bridging the Gap. An independent science journalist based in the San Francisco Bay Area, he covers a wide range of subjects, including environmental health, neuroscience, and pharmacology.

Project CBD feedback request: Have you used a CBD-rich topical product? What’s been your experience? Let us know

References:

1. Lefebvre, È.; Tawil, N.; Yahia, L. Transdermal Delivery of Cannabidiol for the Management of Acute Inflammatory Pain: A Comprehensive Review of the Literature. Int. J. Mol. Sci. 2024, 25, 5858. https://doi.org/10.3390/ijms25115858

2. Scholfield, CN; Waranuch, N; Kongkaew, C. Systematic Review on Transdermal/Topical Cannabidiol Trials: A Reconsidered Way Forward Cannabis and Cannabinoid Research 2023 8:4, 589-602

3. Pastina JT, Abel, MG, Bollinger, LM, Best, SA. Topical Cannabidiol Application May Not Attenuate Muscle Soreness or Improve Performance: A Randomized, Double-Blinded, Placebo-Controlled Pilot Study. Cannabis and Cannabinoid Research 9 July 2024, https://doi.org/10.1089/can.2024.001

4. Haffar, Amer et al., Topical Cannabidiol (CBD) After Total Knee Arthroplasty Does Not Decrease Pain or Opioid Use: A Prospective Randomized Double-Blinded Placebo-Controlled Trial, Journal of Arthroplasty, Volume 37, Issue 9, 1763 – 1770

5. Heineman, John T. et al. A Randomized Controlled Trial of Topical Cannabidiol for the Treatment of Thumb Basal Joint Arthritis. Journal of Hand Surgery, Volume 47, Issue 7, 611 – 620

6. Bawa, Z., Lewis, D., Gavin, P.D. et al. An open-label feasibility trial of transdermal cannabidiol for hand osteoarthritis. Sci Rep 14, 11792 (2024). https://doi.org/10.1038/s41598-024-62428-x

Acknowledgement: This article was made possible by a grant from OP6 CBD. Project CBD is able to exist due to the organizations and brands who support our work financially. Our contributing journalists and researchers operate independently of any influence from our supporting partners.

The post CBD Topical Medicine: What Does the Science Say? appeared first on Project CBD.

**p

Consider it a testament to the ubiquity and flexibility of the endocannabinoid system: we can inhale medicinal cannabinoids via combustion or vaporization;

.🚨🐶Looking for a healthy dog treat? Our Live Green H**p CBD treats for dogs are a quick and easy method to give your bes...
03/07/2025

.🚨🐶Looking for a healthy dog treat? Our Live Green H**p CBD treats for dogs are a quick and easy method to give your best friend the right amount of pure, h**p-derived CBD in a tasty, crunchy hard chew that he'll love. 💕
Intoxicating H**p Swindle

A new study from an industry advocacy group in California examines the content of dozens of unregulated intoxicating “h**p” products that are easily available in the Golden State despite being banned by state law.

The study, entitled “The Great H**p Hoax,” was released Feb. 13 by the San Diego/Imperial Counties Joint Labor Management Cannabis Committee — made up of representatives of UFCW Local 135, and local companies March & Ash and Embarc. Its provocative kicker states: “Much of what’s sold as ‘h**p’ today isn’t h**p at all — it’s a mix of synthetic intoxicants and illicit THC masquerading as a legal, natural product.”

The report’s lead author is Tiffany Devitt of Groundwork Holdings, Inc., the parent company of March & Ash and CannaCraft. For the study, Infinite Chemical Analysis Labs of San Diego examined 104 products marketed as “h**p” — mostly chewable gummies and v**es — that were purchased online from 68 brands. These include well-known names like Cookies, Cheech and Chong, Cali Extrax, Dome Wrecker, Torch, and Cake.

The study’s findings indicate that many so-called h**p products are infused with synthetic psychoactive cannabinoids, which can actually make users feel loopier than natural Delta-9 THC. What’s more, synthesized Delta-9 THC is present in many of these products, despite being prohibited in both California’s cannabis and h**p programs. And finally, these products, mostly vended through websites, are effectively dodging the taxman — raising no revenues for state or local governments.

‘H**p’ not really h**p

Speaking in a Feb. 12 online press conference, Devitt stated: “We’ve been watching the h**p industry emerge, and it’s exploded into a marketplace of highly intoxicating products. The real head-scratcher for us is that h**p is actually a really inefficient plant from which to make naturally psychoactive products.”

Explains Devitt: “If I’m going to extract or source Delta-9 THC from h**p rather than [high-resin] cannabis, I’m going to need around 50 times more biomass, which means 50 times more acreage, 50 times more labor, 50 times more water, et cetera, et cetera, [to make a small amount of THC distillate.] And the picture for Delta-8 is even more shocking, because there’s less natural Delta-8 THC in h**p than there is Delta-9 . . . If I’m using naturally extracted Delta-8 from h**p, it’s going to take about 19 pounds of biomass to make a 2-gram cartridge.”

This pointed right away to industry corner-cutting. If the THC is not coming directly from the plant, then where is it coming from? And what’s actually in psychoactive products labeled as “h**p”? The study found that these products are chock full of synthesized compounds that can be more potent — and riskier — than the natural cannabinoids found in the plant.

The study defines “chemically synthesized cannabinoids” as compounds made through a chemical conversion process rather than being naturally extracted from the plant. These can include Delta-8 and Delta-9 THC, which are typically synthesized from CBD isolate that’s sourced from h**p. There’s also THCP, THCO, HHC, and others that can’t be made from CBD starter material — and thus are outside the legal definition of “h**p.” These illegal compounds are designed to mimic the effects of Delta-9 THC but are often chemically modified to amplify intoxicating effects. THCP, for example, is estimated to be over 30 times stronger than Delta-9 THC.

The study arrived at a “THC Potency Equivalency Factor” (PEF) based on each compound’s relative CB1 (cannabinoid) receptor binding affinity compared to natural delta-9 THC. THCP was found to have a PEF of 30 — meaning it is 30 times more efficacious at getting you high than its natural cousin Delta-9 THC. “This can also mean amplified health risks,” says Devitt, who compares THCP and other “uber-strong” designer compounds identified in the study to the street drug Spice. Also known as K2, this is basically any herbaceous substance treated with synthetic molecules that overwhelm or trip-switch the CB1 receptor.

It’s not nice to fool Mother Nature

Sloppy language in the 2018 US Farm Bill inadvertently opened this “Pandora’s box” of unregulated psychoactive designer compounds by legalizing cannabinoids other than Delta-9 THC that were derived from “h**p” as defined by federal law — that is, cannabis with under 0.3 percent THC. This was intended as a means of day-lighting CBD, the non-psychoactive (or perhaps very subtly psychoactive) cannabinoid with a plethora of purported curative properties. A glut of CBD flooded the market after the passage of the Farm Bill, and this set the stage for intoxicating h**p entrepreneurs, who took advantage of the CBD’s trickster-like ability to shape-shift — or be shape-shifted — into Delta-8 or Delta-9 THC via a chemical conversion process.

For some perspective on the matter, Project CBD turned to Marc Scialdone, a molecular chemist with Saint Michael’s College in Vermont, who co-authored a 2023 paper for the International Cannabinoid Research Society (ICRS) entitled “The Dark Side of Cannabidiol.” “Before the Farm Bill, extracted CBD was $5,000 per kilo; since the Farm Bill, it’s down to $200,” Scialdone explained. “The market crashed. There was an incentive to take a material nobody wants to buy and create a product from it that there’s a demand for. People want to get high.”

However, a major problem: intoxicating “h**p” products, poorly manufactured without meaningful oversight, often contain THC isomers not found in nature. The “H**p Hoax” study identified these and other byproducts of the chemical conversion process, including corrosive solvents and heavy metals, which found their way into gummies and v**e carts. As Scialdone pointed out, it’s technically difficult and prohibitively expensive to filter out residual toxins in adulterated products after CBD has been synthesized into THC — which may not bode well for public health given the booming market for “h**p” intoxicants.

Golden State officials have taken steps to rein in the Wild West of psychoactive “h**p” commerce. California’s Assembly Bill 45, passed in 2021, explicitly states: “‘Industrial h**p’ does not include cannabinoids produced through chemical synthesis.” AB 45 also instated a definition of “Total THC,” adding all “intoxicating” cannabinoids to the sum — not just Delta-9. If the Total THC in a given product exceeds the 0.3% limit, then the product is deemed to be in violation of California’s h**p regulations.

Gumming up clarity on gummies

The study tested potency and checked to see if products complied with the legal definition of h**p. Disturbingly, it found that a full 54% of products tested failed to meet the federal h**p standard (based on Delta-9), and 88% failed to meet the California h**p standard (which also includes Delta-8).

A full 95% of products tested contained synthetic cannabinoids, including 97% of v**es and 90% of gummies. Delta-8 was found in 86% of products, Delta-9 in 84%, “uber-strong” THCP in 47%, HHC% in 34, and THCO in 6%.

Devitt says many of the so-called “h**p” gummies contained “astonishing levels” of THC that were significantly higher than what’s permitted in California’s regulated cannabis market, which abides by a per serving THC cap of 10 milligrams and a per package cap of 100 milligrams. A full 84% of tested gummies exceeded the serving cap, with the average THC per gummy weighing in at 89 milligrams. Over a third had between 100 and 325 milligrams. And 81% exceeded the per package cap.

These products continue to be available despite emergency regulations proposed by the California Department of Public Health and signed into effect by Gov. Gavin Newsom in September 2024, which banned any detectable amount of THC in h**p products (including Delta-8 and Delta-9). These emergency regulations were challenged in the courts by the US H**p Roundtable, but they were upheld and remain in effect.

The v**e of things to come?

The study’s findings with v**es are even more ominous. Synthetic cannabinoids were present in a full 97% of v**e products tested, and often these compounds were much stronger than naturally derived THC. According to the study’s “THC equivalency” scale, the average amount of THC in tested v**es was 2,682 milligrams per cartridge — 268% above California’s limit for THC in adult-use cannabis v**e products, which is 1,000 milligrams, and also well above the cap for such products under the state medical ma*****na program, which is 2,000. Over half of tested products contained between 2,000 and 14,000 milligrams of THC equivalency per v**e. This was mostly attributable to THCP.

“With greater potency comes a risk of unintentional over-intoxication,” says Devitt, “and these risks are amplified by exposure to adulterants and the mislabeling of products, so consumers don’t have a clear idea what they are using.”

The study found that some products marketed as supposedly legal “THCA” v**es contained synthetic Delta-8 and THCP but no nonpsychoactive THCA at all. Such was the case with v**e carts hawked by Cookies.

Devitt expresses serious safety concerns. She sees a potential for v**e-related lung damage similar to the nationwide outbreak of hundreds of pulmonary injuries, some fatal, that researchers linked to va**ng in 2019. These injuries involved either ni****ne products or cannabis oil concentrates.

‘Shrooms and Kratom

Perhaps most surprisingly, the study detected in several products additional psychoactive compounds that have nothing to do with h**p or cannabis at all — including psilocybin mushrooms, or molecules derived thereof. Even in very minute quantities, these clearly could be a shortcut to a longer and stranger trip than the user may have bargained for.

Found in more of these products was kratom, a somewhat controversial substance, which the report describes as an “addictive, opiate-like herb.” Yet its advocates tout its ability to help wean users off opioids. In response to its growing popularity, the DEA announced in 2016 that kratom would be placed in the restrictive Schedule I — along with cannabis. However, the following year the DEA put off its decision pending further public commentary.

Among the products containing kratom are Cheech & Chong’s Kosmic Chews — marketed under the brand name of the infamous counterculture comedy duo. Each Kosmic Chew has 25 milligrams of kratom, as well as 15 milligrams of THC. This information is listed on the label, which promises a “deeper high.” However, the fine print notes that “some people have developed kratom dependency after prolonged daily use.”

Devitt takes issue with the claim on the label of Kosmic Chews that the product contains “all natural” Delta-9 THC. The company website boasts: “No synthetic chemicals. Just 100% naturally occurring REAL THC, from American-grown h**p…” But, as noted in the study, the Infinite Chemical Testing Lab found that Kosmic Chews contained chemically synthesized THC, which has been prohibited in California h**p products since 2021.

When contacted by Project CBD, Brandon Harshbarger, president of Cheech & Chong’s Global Holding Company, maintained that the 2018 Farm Bill legalized h**p-derived THC products, and Kosmic Chews are within the 0.3% federal THC limit. He also claimed there’s no evidence Kratom interacts adversely with THC. “The combination of h**p-derived Delta-9 THC and kratom extract in Kosmic Chews is not inherently dangerous when consumed responsibly,” according to Harshbarger. “Each ingredient has a well-documented safety profile at the included doses.”

Tiffany Devitt’s response: “As Cheech & Chong are well aware, businesses are subject to federal and state laws. In California, THC-infused h**p products are banned. Period. There’s no ambiguity or loophole. There is a bright, clearly drawn line, and they’re crossing it.”

Taxation and transparency

What Devitt calls an “incidental finding of the study” is that a full 91% of products were purchased with no state or local taxes.

Says Devitt: “There’s no cannabis excise tax, even though they are selling psychoactive cannabis products. This not only deprives the state of tax revenues. It also widens the price gap between psychoactive ‘h**p’ products and better quality cannabis comestibles, to the detriment of the legal adult-use cannabis industry.”

Devitt also feels there are issues of democracy at play here. “The legal cannabis market was developed through Prop 64 and a voter mandate,” she says, referring to the 2016 ballot initiative that legalized adult use of the herb in the Golden State. “It was crafted to provide accountability and transparency throughout the supply chain — with lab testing, track-and-trace programs and tax collection mandated. The h**p market remains chaotic and opaque.”

Globalized gray market

The report raises special concern about the transparency of sourcing intoxicating h**p ingredients. It states: “California’s cannabis industry…supports strong labor protections and well-paying union jobs. In contrast, many ‘h**p’ companies manufacture products out of state or import inputs from China, bypassing labor standards and contributing nothing to California’s workforce.”

Despite its own extremely harsh internal drug laws — which definitely extend to cannabis — China has in fact been cashing in on the cannabis boom by growing h**p and extracting CBD for the global market. In May 2022, the United Nations Office on Drugs & Crime (UNODC) issued a report finding that a “new generation of synthetic cannabinoid receptor agonists” were “circumventing legal controls” in China as well as Singapore. Apparently, producers once again were tweaking molecules to stay one step ahead of the law. And THCP continues to be available in bulk on the AliBaba ecommerce website.

Marc Scialdone suspects that most synthetic cannabinoids available domestically are derived from h**p-extracted CBD produced in the United States. But he acknowledges that the lack of transparency means it’s hard to know for sure. “There’s a commodity market for these compounds,” he says. “It’s like white sugar — when you buy it, you don’t necessarily know where it comes from.”

Fueling an anti-cannabis backlash

A final bitter twist to this is that concerns over this unregulated sector of intoxicating products (which are not actually meaningfully related to h**p) have led to calls to place more burdensome restrictions on the regulated cannabis sector. There has been a rash of bills in several states to raise taxes and permit fees on cannabis business to prohibitive levels, or to ban smokable flower from state-licensed medical ma*****na programs. It’s a matter of stigmatization by association, according to the Green Market Report (Feb. 18), which noted: “The political backlash has been fueled in large part by the burgeoning intoxicating h**p industry, which generally operates without any of the state-level guardrails that have been established to keep ma*****na businesses in check.”

A New York Times story (Jan. 25), “The Race for All-Powerful Pot,” depicted the legal cannabis industry in “a race to the bottom,” resorting to corner-cutting tricks like dusting joints with THC concentrate (which is certainly an affront to old-school growers). Among the factors driving this fast-buck atmosphere: “[T]he industry faces a growing threat from intoxicating h**p-derived compounds such as Delta-8, which can be sold more widely and with fewer restrictions.”

The elephant in the room is the apparent lack of concern regarding the health implications of distributing contaminated synthetic “h**p” derivatives into the consumer market. “I cannot imagine another legitimate industry that would be permitted to operate with such irresponsibility,” says Christopher Hudalla of Proverde Labs in Massachusetts. Yet this issue is rarely broached by product-makers, journalists, and lawyers when discussing the economic advantages enjoyed by counterfeit h**p entrepreneurs who benefit from operating on an unlevel playing field.

“Today’s unregulated “h**p” industry isn’t about wellness or even h**p itself. It’s about making a fast buck by selling synthetic cannabis substitutes under misleading branding while ignoring the health and safety of consumers,” says Devitt. “Intoxicating h**p products are the cannabis equivalent of ultra-processed junk food. They make a mockery of the medical roots of the cannabis industry. And they have nothing to do with ecologically beneficial fiber h**p and nutritious h**pseed oil that have gotten short shrift since the passage of the Farm Bill.”

# # #

Bill Weinberg is an award-winning journalist in fields of human rights, drug policy, ecology and war. He is producer of the website and podcast CounterVortex.org.

The post Intoxicating H**p Swindle appeared first on Project CBD.

**p

California lab tests expose massive fraud, illegal products & the cannabis equivalent of ultra-processed junk food

Address

Davie, FL

Opening Hours

Monday 9am - 6:30pm
Tuesday 9am - 6:30pm
Wednesday 9am - 6:30pm
Thursday 9am - 6:30pm
Friday 9am - 6:30pm

Alerts

Be the first to know and let us send you an email when Live Green Hemp posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Business

Send a message to Live Green Hemp:

Share